Inloggad som:

avslutad_MK6482-012

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_MK6482-012
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag
https://clinicaltrials.gov/ct2/show/NCT04736706

Studien ändrades senast av: studysonia (2023-06-27)

Tillbaka till listan